Sue Eckhardt
Medical Oncology · Austin, TXNPI 1043300726
Payments from drug & device makers
Across 78 payments — averaging $18,848 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exelixis Inc.$1.4M
- Amgen$25K
- Novartis$18K
- Merck$10K
Across 1 payment — averaging $2920.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$29,3602%
- Speaking & faculty fees$1,399,67496%
- Travel & lodging$18,0021%
- Food & beverage$4,6290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exelixis Inc. | 45 | $1,416,582 |
| Amgen | 20 | $25,111 |
| Novartis | 1 | $18,480 |
| Merck | 12 | $9,972 |
How this compares
$1,470,146 in reported general payments places this provider in the 75th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Austin
- Jason MelearAustin$14.1M
- Hagop KantarjianHouston$100.5M
- Timothy YapHouston$56.7M
- Yasir ElaminHouston$41.3M
- David HongHouston$31.6M
- Guillermo Garcia-ManeroHouston$31.6M
- Jason WestinHouston$30.8M
- Sawsan RashdanDallas$29.9M
- Lucia MasarovaHouston$29.7M
- Jordi Rodon AhnertHouston$28.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.